1. A Phase I/II Study of Mycophenolate Mofetil in Combination with Cyclosporine for Prophylaxis of Acute Graft-versus-Host Disease after Myeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation 
Richard A. Nash, Laura Johnston, Pablo Parker, Jeannine S. McCune, Barry Storer, John T. Slattery, Terry Furlong, Claudio Anasetti, Frederick R. Appelbaum, Michele E. Lloid, H. Joachim Deeg, Hans-Peter Kiem, Paul J. Martin, Mark M. Schubert, Robert P. Witherspoon, Stephen J. Forman, Karl G. Blume, Rainer Storb 
Biology of Blood and Marrow Transplantation 
Volume 11, Issue 7, Pages (July 2005)
DOI: /j.bbmt
Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
CSP and MMF for GVHD prophylaxis: MPA pharmacokinetics for days 0, 7, 14, 21, and 27 after allogeneic HCT. MMF (15 mg/kg) was administered every 12, 8, and 6 hours from days 0 to 27. The pharmacokinetic studies were completed on days 0, 7, and 14 while patients were receiving only the intravenous formulation of MMF (A-C). Only the data from patients who received the oral formulation of MMF are presented in the day 21 pharmacokinetic studies (D). There were limited data on day 27 pharmacokinetic studies, and therefore these data are not presented in the figure.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Incidence of grade II to IV acute GVHD with 3 different total daily doses of MMF. The incidence of GVHD was 40%, 62%, and 70% at the MMF daily doses of 30, 45, and 60 mg/kg, respectively.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions